- Report
- September 2024
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- April 2024
- 160 Pages
Global
From €4742EUR$4,969USD£3,973GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- March 2024
- 397 Pages
Global
From €7587EUR$7,950USD£6,357GBP
From €2625EUR$2,750USD£2,199GBP
- Report
- April 2023
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- March 2019
- 39 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- January 2025
- 91 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2022
- 83 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP

Lurasidone is a medication used to treat mental disorders such as schizophrenia and bipolar disorder. It is an atypical antipsychotic drug that works by blocking certain receptors in the brain, which helps to reduce symptoms such as hallucinations, delusions, and disorganized thinking. It is also used to treat depression and anxiety. Lurasidone is generally well-tolerated and has fewer side effects than other antipsychotic medications.
The lurasidone market is a growing segment of the mental disorders drugs market. It is a relatively new drug, having been approved by the FDA in 2009, and is gaining popularity due to its effectiveness and low side effects. It is used in both the short-term and long-term treatment of mental disorders.
Some companies in the lurasidone market include Sunovion Pharmaceuticals, Intas Pharmaceuticals, and Dr. Reddy's Laboratories. Show Less Read more